Axogen Inc AXGN
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if AXGN is a good fit for your portfolio.
News
-
Axogen, Inc. to Report First Quarter 2024 Financial Results and Host Conference Call on May 2, 2024
-
Axogen, Inc Reports 2023 Fourth Quarter and Full-Year Financial Results
-
Axogen, Inc. to Report 2023 Fourth Quarter and Full-Year Financial Results on March 5, 2024
-
Company Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Trading Information
- Previous Close Price
- $6.86
- Day Range
- $6.78–7.15
- 52-Week Range
- $3.45–10.83
- Bid/Ask
- $6.95 / $6.96
- Market Cap
- $304.50 Mil
- Volume/Avg
- 131,828 / 395,212
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 1.85
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Axogen Inc is engaged in the science, development, and commercialization of technologies for peripheral nerve regeneration and repair. The company provides clinically, economically effective repair solutions for surgeons and health care providers. Its products include Avance Nerve Graft, Axoguard Nerve Connector, Axoguard Nerve Protector, Axoguard Nerve Cap, and Avive Soft Tissue Membrane. It also offers an Axotouch Two-Point Discriminator used to measure the innervation density of any surface area of the skin. Its products are available in the United States, Canada, Germany, the United Kingdom, Spain, South Korea, and several other countries.
- Sector
- Healthcare
- Industry
- Medical Devices
- Stock Style Box
- Small Core
- Total Number of Employees
- 428
- Website
- https://www.axogeninc.com
Comparables
Valuation
|
Metric
|
AXGN
|
MDXG
|
7XC
|
|---|---|---|---|
Price/Earnings (Normalized) | — | 66.97 | — |
Price/Book Value | 3.09 | 6.52 | — |
Price/Sales | 1.85 | 2.89 | — |
Price/Cash Flow | — | 17.40 | — |
Price/Earnings
AXGN
MDXG
7XC
Financial Strength
|
Metric
|
AXGN
|
MDXG
|
7XC
|
|---|---|---|---|
Quick Ratio | 1.85 | 2.95 | 3.78 |
Current Ratio | 2.89 | 3.57 | 4.66 |
Interest Coverage | −6.66 | 5.74 | −28.71 |
Quick Ratio
AXGN
MDXG
7XC
Profitability
|
Metric
|
AXGN
|
MDXG
|
7XC
|
|---|---|---|---|
Return on Assets (Normalized) | −3.53% | 12.48% | −0.01% |
Return on Equity (Normalized) | −6.99% | 123.45% | −0.02% |
Return on Invested Capital (Normalized) | −2.42% | 42.32% | −0.22% |
Return on Assets
AXGN
MDXG
7XC
Medical Devices Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
ABT
| Abbott Laboratories | Mckwvvvt | Kzytnm | $185.8 Bil | |
SYK
| Stryker Corp | Cynyzbcjh | Qbxj | $124.7 Bil | |
MDT
| Medtronic PLC | Ytrchmydq | Zrlbyg | $105.2 Bil | |
BSX
| Boston Scientific Corp | Twxcvlk | Pflnlk | $99.0 Bil | |
EW
| Edwards Lifesciences Corp | Zthcvbjtj | Wjhnzh | $52.3 Bil | |
DXCM
| DexCom Inc | Tbmlynxzqw | Xclm | $52.1 Bil | |
ZBH
| Zimmer Biomet Holdings Inc | Wbyqmnzch | Mpqdj | $24.8 Bil | |
ALGN
| Align Technology Inc | Dclsmsbv | Rzpps | $22.6 Bil | |
PHG
| Koninklijke Philips NV ADR | Zzxrjvv | Lvshvq | $18.5 Bil | |
PODD
| Insulet Corp | Kzksjgck | Szlyvf | $11.5 Bil |